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1015-9584/Copyright ª 2016, Asian Su
NC-ND license (http://creativecommoSummary Background: Dexmedetomidine has been proposed as a novel anesthetic adjuvant.
However, it remains unclear whether peripheral administration of dexmedetomidine is safe
and effective to reduce acute postoperative pain. This study aimed to examine the effects
of dexmedetomidine on neuropathic pain.
Methods: Adult male Sprague-Dawley rats were anaesthetized and randomly allocated into
four groups (n Z 8): Groups S, R, RD1, and RD5 were injected with saline, 0.5% ropivacaine,
0.5% ropivacaine combined with 1 mg dexmedetomidine, and 0.5% ropivacaine combined with
5 mg dexmedetomidine, respectively, around the saphenous nerve. Then, the rats were sub-
jected to skin/muscle incision and retraction (SMIR) surgery in the medial thigh. Mechanical
and heat sensitivity was evaluated and morphology of the dorsal root ganglion (DRG) neurons
was observed by electron microscopy.
Results: Some 62.5%, 50%, 12.5%, and 25% of rats developed mechanical hypersensitivity in
Groups S, R, RD1, and RD5, respectively. The number of swollen mitochondria in DRG neurons
was significantly more in Group S (257.2  60.9) and Group R (291.6  82.1) than in Group RD1
(97.2  33.3) and Group RD5 (13.6  17.9). In addition, the edema in endoplasmic reticulum
and Golgi apparatus was decreased in Group RD1 and Group RD5 compared with Group S and
Group R.
Conclusion: Peripheral administration of dexmedetomidine improves mechanical and heat hy-
peralgesia and mitigates postoperative pain.
Copyright ª 2016, Asian Surgical Association. Published by Elsevier Taiwan LLC. This is an open
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36 X. Huang et al.1. IntroductionOpen inguinal hernia repair is one of the most painful
procedures in surgery because it involves essential pro-
longed tissue retraction and often causes persistent post-
operative pain. Local anesthetic into the retraction site can
reduce the postoperative pain and reduce the dosage of
morphine, which can prolong the first usage of morphine.1,2
Since the clinical introduction of ropivacaine, its safety in
the central nervous and cardiovascular systems compared
with bupivacaine has attracted attention.3 Ropivacaine is
also widely used for infiltration anesthesia in Europe.4e6
However, the local pharmacokinetics of ropivacaine show
that the effects of infiltration anesthesia with ropivacaine
on the dental pulp are not as strong as expected, because it
has a high affinity for soft tissue.6 To compensate for this
weakness, clinical practitioners favored adding some ad-
juvants to ropivacaine.
A recent study showed that local injection of a novel a2
receptor agonist dexmedetomidine enhanced the local
anesthetic potency of lidocaine via the a2A adrenoceptor
subtype in guinea pigs; dexmedetomidine at a concentra-
tion of 1mM induced peripheral vasoconstriction without a
systemic cardiovascular response via the peripheral a2A
adrenoceptor subtype.7
The nerve endings of dorsal root ganglion (DRG) neurons
have a variety of sensory receptors that are activated by
mechanical, thermal, chemical, and noxious stimuli. The
changes in structure and gene expression in DRG neurons
appear to contribute to the development of neuropathic
pain. However, no study has shown whether the peripheral
administration of dexmedetomidine is safe and effective
for reducing acute postoperative pain. In addition, the ef-
fects of dexmedetomidine on substructural changes in DRG
neurons remain unclear. This study aimed to investigate the
effects of dexmedetomidine on neuropathic pain after
inguinal hernia repair surgery. To mimic the clinical sce-
nario, a model of skin/muscle incision and retraction (SMIR)
in the medial thigh has been established to evoke persistent
postoperative pain. In this study, we used the SMIR model to
examine the effects of dexmedetomidine on neuropathic
pain and substructures in DRG neurons.
2. Materials and methods
2.1. Animals
Adult male Sprague-Dawley rats (200e300 g) were housed
in pairs in plastic cages. Artificial lighting was provided on a
fixed 12:12 hour light/dark cycle (7:00 AM light on) with
free access to food and water. This study was conducted
based on the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. Animal studies were approved by the Animal Care
and Use Committee of Southern Medical University.
2.2. Surgery procedures
Rats were anaesthetized with i.p. 10% chloral hydrate
(100 mg/mL) at dose of 400 mg/kg, laid on their back, andthe medial thigh on one side was shaved. The shaved skin
was then swabbed with sterile alcohol wipes for the ster-
ilization and visualization of the saphenous vein. The rats
were randomly allocated into four groups (n Z 8): Group R
was injected with 0.5% ropivacaine around the saphenous
nerve; Group RD1 was injected with 0.5% ropivacaine
combined with 1 mg dexmedetomidine around the saphe-
nous nerve; Group RD5 was injected with 0.5% ropivacaine
combined with 5 mg dexmedetomidine around the saphe-
nous nerve; and Group S was injected with 0.9% saline
around the saphenous nerve.
An incision of 1.5e2 cm was made in the skin of the
medial thigh approximately 4 mm medial to the saphenous
vein. An incision (7e10 mm long) was then made in the
superficial (gracilis) muscle layer of the thigh, approxi-
mately 4 mm medial to the saphenous nerve. The super-
ficial muscle was then parted further, by spreading blunt
scissors within the muscle incision site, to allow the
insertion of a micro dissecting retractor. The retractor had
four prongs spaced over 8 mm and each prong was 4 mm
deep (Cat. No. 13-1090, Biomedical Research Instruments
Inc., Silver Spring, MD, USA). The retractor was inserted
into the incision site, to position all prongs underneath the
superficial layer of thigh muscle. The skin and superficial
muscle of the thigh were then retracted by 2 cm and the
retraction was maintained for 1 hour. During the retrac-
tion, the saphenous nerve was displaced and potentially
stretched around the retractor. The animals were moni-
tored during the retraction period and if required, addi-
tional anesthesia was provided using chloral hydrate.
During the retraction period, animals were completely
covered (apart from the top of the head) with a large
absorbent bench underpad to minimize heat loss and
prevent dehydration of the surgical site. Following the
SMIR procedure, the muscle and skin of the surgical site
was closed with silk 3.0 and 4.0 Vicryl sutures, respec-
tively. Sham-operated rats underwent the same procedure
with the exception of the skin/muscle retraction.
Following recovery from anesthesia, all animals could rise
up on their hindpaws to reach food and water.
2.3. Assessment of mechanical sensitivity
Mechanical sensitivity was assessed using the up-down
method as described previously.8 Briefly, rats were placed
inside acrylic cages on a wire mesh grid floor. The probe
was applied to the middle of the left hind paw to determine
the stimulus intensity threshold stiffness. Quick withdrawal
in response to the stimulus was considered to be a positive
response.
2.4. Assessment of heat sensitivity
Animals were placed in individual Perspex boxes on a glass
floor. Nociceptive responses to a noxious heat stimulus
were examined by measuring the hindpaw withdrawal la-
tency from a focused beam of radiant heat to the plantar
surface (Ugo Basile plantar test apparatus, Monvalle, Italy).
The withdrawal latency to this stimulus was measured in
seconds and the apparatus had a build-in cut-off latency of
31.2 seconds. Both hindpaws of each rat were tested three
Figure 1 Mechanical pain threshold of four groups. Ipsilat-
eral paw response to von Frey stimulation was severe in Group
S compared with Group R and RD1 during the postoperative
time course, and it was significantly milder in Group RD1 and
RD5 than in the other two groups at Day 14. Group RD1 was
injected with 0.5% ropivacaine combined with 1 mg dexmede-
tomidine. Group RD5 was injected with 0.5% ropivacaine com-
bined with 5 mg dexmedetomidine. Group S was injected with
0.9% saline before surgery. Group R was injected with 0.5%
ropivacaine.
Dexmedetomidine reduces neuropathic pain 37times and then an average of these three readings taken.
To avoid sensitization of the paws, several minutes had
elapsed before the same hindpaw was retested.
2.5. General toxicity
Body weights were measured before each injection and
behavioral assessments. All rats were examined daily for
piloerection, alopecia, fecal abnormalities, and diet
situation.
2.6. Transmission electron microscopy
At the end of the experiments, the rats were killed and
DRGs were dissected. DRGs were cut into sections and fixed
in 2.5% glutaraldehyde in 0.01 mol/L phosphate buffer,
followed by 2% osmium tetroxide. Next, the sections were
dehydrated in a series of graded ethanol solutions and
embedded in epoxy resin. Ultrathin sections were double-
stained with uranyl acetate and lead, and examined under
a JEM1200EX transmission electron microscope (Jeol,
Tokyo, Japan).
2.7. Statistical analysis
Data were expressed as the mean  standard deviation and
analyzed using SPSS version 12 statistical analysis package
(SPSS Inc., Chicago, IL, USA). A p value < 0.05 was accepted
as statistically significant.3. Results3.1. Assessment of general condition
All rats regularly received four injections as described and
no animals died during the experiments. Furthermore, no
recession in motor activity was observed and no abnormal
clinical symptoms such as alopecia, anorexia, and diarrhea
were observed. All rats continued to gain weight steadily,
and no significant differences in the weight were observed
among the groups.
3.2. Assessment of mechanical sensitivity
For the mechanical sensitivity test, no significant differ-
ences existed among the groups at baseline (Figure 1).
However, SMIR group rats had pronounced and prolonged
mechano-hyperalgesia after the first injection compared
with the other three groups. Group R, Group RD1, and
Group RD5 rats had milder and shorter pain behaviors than
Group S within the study period. In Group S, mechano-
hyperalgesia was obvious from Day 1 and lasted until Day
5 (Figure 1). In Group R and Group RD1, mechano-
hyperalgesia was obvious from Day 1 and lasted until Day
3. In Group RD5, mechano-hyperalgesia was obvious from
Day 1, peaked at Day 5, and lasted until Day 5 (Figure 1).
The detailed data of mechanical pain threshold of the four
groups are listed in Table 1.3.3. Assessment of heat sensitivity
For the heat sensitivity test, no significant differences
existed among the groups at baseline (Figure 2). The rats in
Group S showed no significant changes in heat sensitivity
throughout the experimental period. The response latency
of group RD1 rats increased significantly from Day 1 until
Day 3, while that of group RD5 rats increased significantly
from Day 3 to Day 5 (Figure 2). We found no significant
difference in response latency between Group S and the
other three groups at other time points (Figure 2, Table 2).
3.4. Evaluation of persistent pain
In this study, five out of a total of eight SMIR-operated rats
generated mechanical hypersensitivity compared with
baseline, indicating that 62.5% of rats in Group S developed
mechanical hypersensitivity at the end of the observational
day (14 days after surgery). In comparison, 50% of rats in
Group R developed mechanical hypersensitivity, which
showed no statistical difference from Group S. In RD1 and
RD5 groups, about 12.5% and 25% of rats developed me-
chanical hypersensitivity, respectively (Figure 3, Table 3,
p < 0.05 compared with Group S).
3.5. Subcellular structure of DRG
By transmission electron microscopy, we found that the
number of swollen mitochondria in DRG was significantly
more in Group S (257.2  60.9) and Group R (291.6  82.1)
than in Group RD1 (97.2  33.3) and Group RD5
(13.6  17.9). In addition, the edema in endoplasmic
Table 1 Mechanical pain threshold of four groups.
Group
(n Z 8)
D0 D1 D3 D5 D7 D14
Group S 20.30  1.20 3.64  0.59 4.52  0.67 3.89  0.88 18.89  0.27 12.88  0.34
Group R 20.24  0.42 6.15  5.90* 5.83  0.73 13.46  0.24 12.36  0.34* 12.43  0.47
Group RD1 20.14  0.40 7.48  3.30* 7.48  0.33* 7.87  0.34 14.27  0.46 22.64  0.68*
Group RD5 21.25  0.44 11.00  3.80* 10.96  0.58* 8.36  0.82 25.37  0.47* 21.88  0.23*
*p < 0.05 versus Group S.
Figure 2 Heat pain latency of four groups. Ipsilateral paw
response to heat was delayed in Groups R, RD1, and RD5
compared with Group S. Group RD1 was injected with 0.5%
ropivacaine combined with 1 mg dexmedetomidine. Group RD5
was injected with 0.5% ropivacaine combined with 5 mg dex-
medetomidine. Group S was injected with 0.9% saline before
surgery. Group R was injected with 0.5% ropivacaine.
Figure 3 Rates of mechanical hypersensitivity of four
groups. Some 62.5% rats developed evoked mechanical hyper-
sensitivity in Group S, 50% rats developed evoked mechanical
hypersensitivity in Group R, 12.5% rats developed evoked me-
chanical hypersensitivity in Group RD1, and 25% rats developed
evoked mechanical hypersensitivity in Group RD5. Group R was
injected with 0.5% ropivacaine before every incision was made.
Group RD1 was injected with 0.5% ropivacaine combined with
1 mg dexmedetomidine. Group RD5 was injected with 0.5%
ropivacaine combined with 5 mg dexmedetomidine. Group S
was injected with 0.9% saline before surgery. Group R was
injected with 0.5% ropivacaine.
38 X. Huang et al.reticulum and Golgi apparatus was decreased in Group RD1
and Group RD5 compared with Group S and Group R
(Figure 4).
4. Discussion
The SMIR model is a novel rat model of persistent post-
operative pain evoked by SMIR, very similar to a clinical
procedure. SMIR-operated rats exhibited at least 3 weeks of
hypersensitivity to mechanical stimulation to the plantar
ipsilateral paw, but SMIR surgery did not evoke mechanical
hypersensitivity in the contralateral paw. The SMIR model isTable 2 Heat pain latency of four groups.
Group
(n Z 8)
D0 D1 D3
Group S 13.13  0.16 15.93  0.43 16.64  0.
Group R 13.64  0.21 14.60  0.72 15.24  0.
Group RD1 13.09  0.69 20.09  0.36* 20.33  0.
Group RD5 13.09  0.23 18.86  0.31 21.96  0.
*p < 0.05 versus Group S.reproducible, with a high proportion of animals operated
over a 10 month period developing SMIR-evoked pain.
Flatters9 demonstrated that SMIR surgery did not induce
significant peripheral neuronal damage, suggesting that
nerve damage is not a causal factor in persistent post-
operative pain evoked by SMIR.
a2 Adrenergic activation leads to analgesic effects.
Dexmedetomidine is an a2 adrenergic agonist that binds to
a2 adrenergic receptors in the central nervous system andD5 D7 D14
77 15.02  0.79 15.09  0.18 14.39  0.34
81 17.03  0.16 20.01  0.35 21.17  0.45*
31* 11.46  0.21 15.97  0.28 19.13  0.61*
59* 21.34  0.53* 17.91  0.32 17.29  0.28
Table 3 Rates of mechanical hypersensitivity of four
groups at day 14 (n Z 8).
Group S Group R Group RD1 Group RD5
Rate 62.5% 50% 12.5%* 25%*
Value below
baseline
5 4 1 2
*p < 0.05 versus Group S.
Dexmedetomidine reduces neuropathic pain 39the spinal cord, and it also binds to imidazoline receptors in
the brain.10 However, the analgesic effect of dexmedeto-
midine added to ropivacaine was not reversed by a1 and a2
adrenoceptor antagonists.11 Dexmedetomidine has been
administered by various routes as the adjuvant to reduce
postoperative pain, such as via the oral, intravenous,
transdermal, intrathecal, and epidural routes.12,13 Howev-
er, there is no study on the long-term effect of ropivacaine
combined with dexmedetomidine. In the current model, we
evaluated the mechanical and thermal sensitivity of the
rats, and our results showed that dexmedetomidine could
strengthen the analgesic effect of ropivacaine and
tremendously reduce postoperative pain when adminis-
tered in peripheral nerve blocks. In addition, no motor
activity and abnormal clinical manifestations were
observed in the rats, and all rats gained weight steadily and
similarly to Group S.Figure 4 Subcellular structure of dorsal root ganglion (DRG) n
endoplasmic reticulum and Golgi apparatus were decreased in Gr
magnification: 8000 . Arrows indicated swollen mitochondria. Gro
was made. Group RD1 was injected with 0.5% ropivacaine combined
ropivacaine combined with 5 mg dexmedetomidine. Group S was in
with 0.5% ropivacaine.Several studies have shown that the addition of dex-
medetomidine accentuated the analgesic efficacy of locally
administered ropivacaine.1e3 Consistent with these studies,
we found that the time to first peak of minimal paw with-
drawal latency was delayed in combined dosage groups,
and paw withdrawal latency was increased in Group RD1
and Group RD5.
Mitochondrial abnormality has been associated with
pain.14 To understand the detailed substructure changes in
DRG after SMIR, we employed electron microscopy and
observed atypical swollen mitochondria in the ipsilateral
paw in the SMIR group. It was hypothesized that paclitaxel
binds to axonal mitochondria and causes mitochondrial
permeability transition pores (mPTPs) to open and release
intracellular calcium. Such an increase in intracellular cal-
cium promotes neuronal hyperexcitability, resulting in pain
behavior.14 In vivo recordings have revealed spontaneous
activity in peripheral nociceptive fibers of paclitaxel-treated
rats and calcium-chelating agents inhibited paclitaxel-
induced pain.15,16 Swollen and vacuolated mitochondria
have been observed in the nerves of patients with painful
peripheral neuropathy induced by 2030-dideoxycytidine.17
Furthermore, mitochondrial abnormality in sensory axons
in paclitaxel-evoked painful peripheral neuropathy contrib-
uted to sensory dysfunction in the rats.18 Therefore, man-
agement of mitochondria abnormality might be a novel
approach for pain control. In the present study, simple
administration of ropivacaine could not reverse theeurons. The swelling of the mitochondria and the edema of
oup RD1 and Group RD5 versus Group S and Group R. Original
up R was injected with 0.5% ropivacaine before every incision
with 1 mg dexmedetomidine. Group RD5 was injected with 0.5%
jected with 0.9% saline before surgery. Group R was injected
40 X. Huang et al.subcellular structure change such as atypical mitochondria
of DRG in the SMIR model within 3 days. However, ropiva-
caine combinedwith a different dosage of dexmedetomidine
markedly decreased mitochondrial abnormality, such as the
number of swollen mitochondria and the level of swelling in
themitochondria. In our future study, wewill collect DRGs at
earlier stage to observe mitochondrial abnormality associ-
ated with pain in acute state.
In conclusion, the addition of dexmedetomidine to
locally administered ropivacaine improves analgesia in the
acute postoperative period in SMIR surgery.
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